On Wednesday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)’s shares declined -2.37% to $129.95.
Vertex Pharmaceuticals Incorporated ( VRTX) declared that administration will take part in a fireside chat at the Morgan Stanley Healthcare Conference in New York, NY on Wednesday, September 16th at 11:40 a.m. ET.
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF); and advancing its research and early-stage development programs. It markets KALYDECO (ivacaftor) to treat patients of six years of age and older with CF who have the mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene in the United States, Australia, Canada, and the European Union. The company also provides INCIVEK for the treatment of adults with genotype 1 hepatitis C virus infection. In addition, it is developing CFTR correctors, counting lumacaftor in combination with ivacaftor, which has accomplished Phase III development program; and VX-661 in combination with ivacaftor, which is in Phase III development program.
Alamos Gold Inc. Class A (NYSE:AGI)’s shares dropped -4.44% to $4.30.
Alamos Gold Inc. (AGI) declared the purchase of 8,000,000 common shares (the “Shares”) of AuRico Metals Inc. (“AuRico”), representing about 6.34% of the outstanding common shares of AuRico (the “Transaction”). The Shares are being attained by Alamos by way of private placement at a price of C$0.70 per Share.
Proceeding to the Transaction, Alamos owned directly 5,767,855 common shares of AuRico, which represented about 4.8% of the issued and outstanding common shares of AuRico. Upon completion of the Transaction, Alamos will hold 13,767,855 common shares of AuRico, representing about 10.92% of the issued and outstanding common shares of AuRico.
Alamos Gold, Inc. operates as an intermediate gold producer primarily in North America. The company primarily holds a 100% interest in the Young-Davidson gold mine, which comprises mineral leases and claims totaling 11,000 acres in Northern Ontario, Canada. It also owns a 100% interest in the El Chanate mine that comprises 22 mineral concessions covering 4,618 hectares; and the Mulatos Mine in Sonora State, Mexico. In addition, the company holds interest in a portfolio of development stage projects in Mexico, Turkey, Canada, and the United States. Alamos Gold, Inc. is headquartered in Toronto, Canada.
At the end of Wednesday’s trade, Quest Diagnostics Inc (NYSE:DGX)‘s shares dipped -1.60% to $65.60.
Quest Diagnostics (DGX), the world’s leading provider of diagnostic information services, recently declared that its Focus Diagnostics products business has received FDA 510(k) clearance to add the genital swab claim to its Simplexa HSV 1 & 2 Direct molecular test on the Integrated Cycler.
The new labeling clearance follows FDA’s de novo 510(k) clearance and CLIA moderate complexity categorization of the Simplexa HSV 1 & 2 Direct molecular test in March 2014. FDA cleared the test at that time for use with cerebrospinal fluid (CSF) from patients suspected of HSV central nervous system (CNS) infection, counting encephalitis, which can be caused by infection with herpes simplex 1 or 2 virus.
Herpes simplex virus type 2 typically causes genital herpes, while herpes simplex virus type 1 typically causes sores around the mouth and lips, although both viruses can cause infection and sores in other locations.
Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company offers clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services, and drugs-of-abuse testing, in addition to related services and insights; laboratory testing services for new drugs, vaccines, and medical devices; analytic, on-site prevention, and wellness services; and risk assessment services for the life insurance industry.
Mentor Graphics Corp (NASDAQ:MENT), ended its Wednesday’s trading session with -1.81% loss, and closed at $24.98.
Mentor Graphics Corporation (MENT) recently declared its newest version of the industry-leading ODB++ intelligent product model, a single and open data structure for transferring printed circuit board (PCB) designs into data for fabrication, assembly and test. The version 8.1 of the ODB++ product model format provides a unique virtual documentation capability that seamlessly translates all data files, drawings, and documents from PCB design through the manufacturing flow.
This open product model format eliminates the need to create and validate disparate documentation content, supporting all electronic design automation (EDA) tool flows. Users of the new ODB++ version will be able to share all the necessary manufacturing instructions as electronic data, making new product introduction (NPI) more efficient for all partners in the supply chain.
Mentor Graphics Corporation provides electronic design automation software and hardware solutions to automate the design, analysis, and testing of electro-mechanical systems, electronic hardware, and embedded systems software.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
